Ildong Pharmaceutical to Participate in BIO USA... "New Drug Pipeline Unveiled"

Ildong Pharmaceutical Headquarters Exterior (Photo by Ildong Pharmaceutical)

[Asia Economy Reporter Kim Ji-hee] Ildong Pharmaceutical announced on the 10th that it will participate in the BIO International Convention (BIO USA) to promote its R&D pipeline and new drug candidates.

BIO USA is the world's largest conference event in the pharmaceutical and biotechnology industry, providing a platform for companies, related professionals, and experts to engage in business and academic exchanges. This year, due to the ongoing impact of COVID-19, the event will be held digitally using online platforms and content, similar to last year. The event will take place from the 14th to the 18th.

Through partnering meetings, Ildong Pharmaceutical plans to focus on introducing its proprietary pipeline, including ▲ID11014, a new drug development project for type 2 diabetes treatment with the GPR40 (G protein-coupled receptor 40) mechanism ▲ID11903, a new drug development project for non-alcoholic steatohepatitis (NASH) with the FXR (farnesoid X receptor) agonist mechanism ▲ID13010, a new drug development project for wet age-related macular degeneration (wAMD) with a dual target mechanism of VEGF-A and NRP-1 ▲ID11041, a new drug development project for dry eye syndrome with the cystic fibrosis transmembrane conductance regulator (CFTR) mechanism ▲ID11901, a new drug development project for acute respiratory distress syndrome (ARDS).

In particular, the type 2 diabetes treatment new drug development project ID11014 (candidate substance name ID16177) is currently awaiting clinical trial approval in Europe. The NASH new drug development project ID11903 is undergoing preclinical trials commissioned to the global new drug development company Evotec. The wet age-related macular degeneration new drug development project ID13010 is producing nonclinical and clinical trial drugs in partnership with a global contract development and manufacturing organization (CDMO).

An Ildong Pharmaceutical official stated, "Through this event, we plan to discover investment and collaboration partners necessary for promoting open innovation, while also exploring licensing-out (technology transfer) opportunities to realize profits."

This content was produced with the assistance of AI translation services.